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Abstract 
 
Introduction & Aims 
Small studies have found that black patient with autoimmune hepatitis (AIH) patients present 
with more aggressive disease. We aimed to characterize the presentation and outcome in 
black and white patients with AIH.  
Methods 
We performed a retrospective study, collecting information from databases of patients with 
AIH attending the Institute of Liver studies at King's College Hospital, London (1971–October 
2015, the Royal Free Hospital, London (1982 through December 2016) and the multicenter 
Dutch Autoimmune Hepatitis Study Group cohort (2006–August 2016). We identified 88 
black patients with AIH and we compared their clinical characteristics and outcomes to 897 
white patients with AIH.  
Results 
Black patients presented at a younger age (median 38 years vs 45 years) (P=.007), had 
higher IgG levels (mean 31.0 mg/dL vs 27.5 mg/dL) (P=.04), but there were no significant 
differences between groups  in auto-antibody profiles, international AIH Group scores, or sex 
distribution of disease. A higher proportion of black patients had systemic lupus 
erythematosus (10%) than white patients (2%) (P=<.001). There was no significant 
difference in proportions of patients with a response to standard therapy (86% for black 
patients vs 91% for white patients; P=.20) or in rate of relapse (57% vs 50%; P=.3). Despite 
this, black patients had an increased risk of liver transplantation and liver-related death 
(hazard ratio 2.4, 95% CI, 1.4–4.0; P<.001). Overall mortality was similar between the two 
groups.  
Conclusion 
In a comparison of black and white patients with AIH in Europe, we found that black patients 
present at a younger age, have higher levels of IgG levels, and a greater proportion have 
SLE. We also found black patients to have a greater risk of liver transplantation and liver-
related mortality, indicating more aggressive disease.   
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Introduction 
Autoimmune hepatitis (AIH) is a rare, chronic progressive immune-mediated inflammatory 
disorder of the liver that affects children and adults.1, 2 It is characterized by female 
predominance, hypergammaglobulinaemia, circulating autoantibodies and interface hepatitis 
on liver biopsy.1 Clinical presentation ranges from asymptomatic biochemical liver 
abnormalities to acute liver failure or cirrhosis.1, 3, 4 Genetic factors play a role in the natural 
history of AIH; white HLA-DRB1*0301 positive AIH type 1 patients are more likely to be male 
and to deteriorate despite steroids and HLA-DRB1*0401 positive patients tend to be older 
and respond better to corticosteroid therapy.5-7 A few studies reported differences in disease 
presentation and outcome between different ethnic groups.8-12 In two studies from the USA 
and the UK it was found that non-Caucasian patients with AIH have more aggressive 
disease at initial presentation, a higher likelihood of cirrhosis being present at diagnosis.9, 10 
A recent population based analysis found that black AIH patients have a higher rate of 
hospitalisation and death during hospitalisation than white patients.13 The difference in 
presentation and outcome between black and non-black patients may in part be genetically 
driven,14, 15 but confounding structural and social factors such as socioeconomic status and 
access to health care have not convincingly been excluded. The studies to date have been 
single centre experiences reporting outcomes with relatively small numbers of patients. We 
aimed to compare the clinical presentation and outcome of black AIH patients from African 
or Caribbean descent in reference to a Caucasian population in a retrospective multicentre 
study. 
 
Methods 
Three well-established and updated databases of patients with AIH attending the Institute of 
Liver studies at King's College Hospital, London, between 1971 and October 2015, The 
Royal Free Hospital, London between 1982 and December 2016, and the multicentre Dutch 
Autoimmune Hepatitis Study Group cohort (DAIHG) between 2006 and August 2016 were 
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reviewed. The King’s College Hospital and the Royal Free Hospital are 2 of 7 liver transplant 
centres in the UK. These liver units treat local patients, but both have large national and 
international referral practices.16 The DAIHG cohort data was updated in 6 academic 
centres, including all 3 Dutch transplant centres, and 10 general referral hospitals.17 Patient 
records were systematically reviewed and examined with regards to self-reported racial 
background as well as clinical characteristics, excluding patients with features of primary 
sclerosing cholangitis and primary biliary cholangitis variant syndromes.  Black background 
was based on self-reported sub-Saharan Africa, Afro-American or Afro-Caribbean origin, 
whereas white background was based on self-reported Caucasian or European origin. In the 
cohort of 985 patients, black race was identified in 88 patients and white race in 897 (Figure 
1). All patients had a clinical diagnosis of probable or definite AIH according to the 1999 
IAIHG scoring system (564 UK and 421 Dutch AIH patients). We compared the black and 
white patient groups in relation to clinical, laboratory and histological features as well as 
treatment outcome, liver transplantation and overall and liver-related mortality.  
As described in previous studies, standard diagnostic criteria for the presence of AIH were 
fulfilled.17, 18 All patients were treated according to standardized protocols published 
previously.19, 20 Response to treatment and relapse were defined in accordance with the 
revised IAIHG criteria.21 Second-line therapy was defined as ever being treated with 
medications other than azathioprine or corticosteroids (including mycophenolate mofetil, 
tacrolimus, cyclosporine A or sirolimus). The presence of concomitant extra-hepatic 
autoimmune disease including celiac disease, autoimmune thyroiditis as well as systemic 
lupus erythematosus (SLE) was retrieved from the patient records. Data on mortality and 
causes of death were retrieved from medical records and/or by contacting the attending 
physicians or general practitioners/family doctors. In the Dutch cohort, liver transplantation 
rates were assessed by cross-checking the clinical record data with the transplantation list 
from all three transplantation centers. Follow-up ended at the date of death or liver 
transplantation, or at the end of the study. This study was approved by the Research Ethics 
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Committee of King's College Hospital (04/Q0703/23), The Royal Free Hospital, London, 
United Kingdom and the ethics committee at the VU University Medical Center, Amsterdam, 
the Netherlands and all the participating centres. In all participating transplant centres, no 
donor organs were obtained from executed prisoners or other institutionalized persons. 
Statistical analysis 
Statistical analysis was performed with IBM SPSS 22.0 (IBM, Armonk, NY, USA) and 
Graphpad Prism 7.02 (GraphPad Software, La Jolla, CA, USA). Demographic and therapy-
specific data are given descriptively as mean and standard deviation (SD) and median and 
interquartile range (IQR) when appropriate. Statistical testing of continuous variables 
between groups was performed with Student's t-test, Mann–Whitney-U-test or Wilcoxon 
signed rank test. Proportional differences were tested with the χ2-test or Fisher's exact test. 
A P-value of <0.05 was considered statistically significant. The primary outcome measure 
was a composite endpoint of liver transplantation and liver-related death. Overall survival 
curves were obtained via Kaplan-Meier’s estimate. For differences in survival between 
groups the Log-rank test and Cox regression analysis was performed, only using time-
independent variables. 
 
Results 
UK-cohort 
The UK cohort consisted of 68 black patients (12%) and 496 white patients (88%). Black 
patients presented at a younger age (median 38 vs 44 years, P=0.05), but the proportion of 
female gender (77 vs 79%, P=0.7), IAIHG scores (20 vs 20, P =0.15) and transaminases 
(median 551 vs 586 IU/L, P=0.9) were similar between both groups. There were no 
differences in ANA, SMA and LKM positivity (Supplementary table 1). Median international 
normalised ratios (INR) for prothrombin time levels were higher (1.3 vs 1.2, P=0.051) and 
albumin levels were lower (32.1 vs 34.4 g/L, P=0.017) in black patients. Black patients more 
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often had concomitant SLE (10 vs 2%, P=0.003) than white patients, but mean IgG levels 
were similar (29.3 vs 27.4 g/L, P=0.3). The median follow-up and associated treatment 
exposure was shorter in the black patients than white patients (103 [IQR 41-149] vs 126 
months [IQR 58-202], P=0.01). The response to standard therapy was significantly lower in 
black patients than white patients (81% vs 93%, P=0.005). Twenty black patients (34%) and 
144 white patients (32%) had cirrhosis at diagnosis (P=0.8). Twelve black patients (18%) 
and 38 white patients (8%) underwent liver transplantation (P=0.007). Sixteen black patients 
(24%) and 67 white patients (14%) reached the combined end-point of liver-transplantation 
and liver-related death (P=0.029).   
Netherlands cohort 
The Netherlands cohort consisted of 20 black patients (5%) and 401 white patients (95%). 
Black patients presented at a younger age (median 38 vs 46 years, P=0.05), but the 
proportion of female gender (75 vs 77%, P=0.8), IAIHG scores (20 vs 18, P=0.3) and 
median transaminase levels (378 vs 492 IU/L, P=0.2) were similar between both groups. 
There were no differences in ANA, SMA and LKM positivity (Supplementary table 2). Median 
INR levels (1.1 vs 1.1, P=0.7) and mean albumin levels (35.8 vs 36.2 g/L, P=0.7) were 
similar in black and white patients respectively. Black patients more often had concomitant 
SLE (10 vs 2%, P=0.08) and had higher mean IgG levels (40.4 vs 27.6 g/L, P=0.001). Two 
black patients (13%) and 56 white patients (19%) had cirrhosis at diagnosis (P=0.7). The 
median follow-up and associated treatment exposure were similar in both groups (181 [IQR 
133-212] vs 178 [IQR 139-239] months, P=0.7). The response to standard therapy were 
similar in both groups (100 vs 89%, P=0.1). One-hundred-eighty-five (38%) patients were 
managed at a transplant centre, whereas the majority of patients was treated at general 
(37%) or non-transplant academic referral (25%) hospitals. Black patients were less often 
managed at transplant (3 [15%] vs 155 [39%], P = 0.03) or academic referral centres (9 
[45%] vs 256 [64%] P = 0.09). The rate of biopsy proven cirrhosis was 19%, which was not 
related to transplant (21%) or academic referral centre (21%). The rates of liver-related 
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death and liver transplantation for all patients were significantly higher in the transplant 
centres than in the general and academic centres (n = 24 [15%] vs n = 12 [5%], P = <0.001). 
No black patients and 11 white patients (3%) underwent liver transplantation (P=1.0). Three 
black patients (15%) and 33 white patients (8%) reached the combined end-point of liver-
transplantation and liver-related death (P=0.2).   
Combined cohort 
The combined study population comprised of 985 patients (736 definite AIH and 259 
probable AIH, black: n=88, white n=897). Black patients presented at a younger age than 
white patients (median 38 vs 45 years, P=0.007), but had similar gender distribution and 
IAIHG post-treatment scores as well as auto-antibody positivity (Table 1). Black patients had 
higher IgG levels (mean 31.0 vs 27.5 g/L, P=0.04) and they had a higher rate of SLE (10% 
vs 2%, P<0.001). There were no differences in age or severity of presentation between black 
patients with and without concomitant SLE. The difference in IgG levels between black and 
white patients persisted after exclusion of patients with SLE (30.4 vs 27.4 g/L, P=0.055. The 
prevalence of cirrhosis at baseline was similar in both groups (29% vs 27%, P=0.5) in the 
822 AIH patients (84%) who underwent liver biopsy at diagnosis. There was a clear 
difference in rates of biopsy proven cirrhosis between the UK and Dutch patients (32 % vs 
19 %, P<0.001). The INR ratios were similar in black and white patients, whereas the 
albumin levels were significantly lower (mean 32.8 vs 35.1 g/L, P=0.005) in black patients. 
Both black and white patients were treated with steroids as standard induction therapy (99% 
vs 95%, P=0.2) and had a similar exposure to azathioprine as maintenance therapy (75% vs 
81 %, P=0.2; Table 2). Black patients had a similar clinical response rates to standard 
therapy compared to white patients (86 % vs 91 %, P=0.2) and also comparable occurrence 
of at least one relapse (57% vs 50% P=0.3). However, during follow-up there was a higher 
proportion total number of recorded relapses in black AIH patients in both the King’s College 
Hospital and the Dutch cohorts (P=0.018). Overall, there was no significant difference in the 
rate of use of second-line therapies (17% vs 11%, P=0.1). 
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Outcome 
The median duration of follow-up in the combined cohort was shorter in the black than in the 
white patients (127 months [IQR: 48-173] vs 152 months [IQR: 91-223], P<0.001). The rate 
of hepatocellular carcinoma (HCC) development was similar in both groups (2% vs 2%, P = 
1.0), but the incidence per 10 patient years was lower in the white patient group (0.018/10 
patient years vs 0.022/10 patient years). The rate of transplantation and liver related death 
was significantly higher in the black patients in the UK cohort (P = 0.029), whereas the rates 
of transplantation, liver-related mortality and overall mortality did not differ significantly 
between black and white patients in the Dutch cohort. In the combined cohort the black AIH 
patients underwent liver transplantation more often than white patients (14% vs 6% 
respectively, P=0.002), but overall mortality was similar between the two groups (11% vs 
15%, P=0.3). Log-rank survival analysis showed an impaired combined transplant-free and 
liver-related mortality for black patients in the combined UK and Dutch cohorts (P<0.001, 
Figure 2A). This was primarily driven by the UK cohort (P<0.001, Figure 2B-C) as the Dutch 
cohort did not reveal a significant association (P=0.4, Figure 2D). This suggest that the 
difference in rates of cirrhosis between the UK and Dutch patients (32% vs 19%, P<0.001) is 
in part driving this association. Cox-regression analysis in the combined UK and Dutch 
cohorts showed an association of black race with liver transplant and liver-related death 
(hazard ratio [HR] 2.4, 95%-confidence interval 1.4-4.0, P=0.001, Table 3), independent of 
age, cirrhosis at diagnosis and SLE in the multivariate analysis. Incorporation of transplant 
centre status and country in the model did not change these results. The presence of 
cirrhosis at diagnosis was associated with an increased risk of liver transplantation or liver 
related death. 
Discussion 
In this retrospective study of black patients with AIH from selected centres in the UK and 
Netherlands  we observed a lower age of onset and a greater risk of liver transplant or liver 
related death, which may illustrate a more aggressive disease course compared to white 
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patients. We also demonstrated that these outcomes occurred in healthcare systems with 
universal access to care, even without a higher likelihood of cirrhosis at diagnosis or without 
an initial inferior apparent treatment responses to induction therapy among black patients. 
Higher IgG levels at diagnosis were noted compared to a white reference population. 
Although no differences in terms of autoantibody profile were noted, black patients more 
often had concomitant SLE. Overall, there was a low rate of HCC and we did not observe an 
association between HCC development and race which is consistent with the similar rates of 
cirrhosis in both groups.22 In both countries and healthcare systems, the vast majority of 
patients received corticosteroids for induction of remission, with azathioprine being added for 
maintenance therapy. Interestingly, there were no differences in terms of response of 
therapy between groups, and a similar proportion of patients needed escalation of therapy 
with second line agents. However, the number of relapses were higher in black patients 
compared to white patients, suggesting that these patients have a more severe disease 
phenotype and are in need of a better maintenance therapy. Alternatively, limited 
compliance to therapy could be factor, although we could not reliably address this issue. Lim 
et al. reported that although both black and white patients responded well to standard 
therapy, the dosage of steroids was significantly higher in black patients despite similar use 
of azathioprine (Table 4.).8 These data suggest that current treatment regimens may be 
inadequate for black patients, and therefore future studies should focus on the development 
of different treatment protocols stratified according to race to address this issue.23, 24 
Importantly, this study also confirms that race also impacts on the natural history of the 
disease, since black patients were more likely to have progressive disease requiring liver 
transplantation. We propose three possible explanations for this outcome. Firstly, and 
although this was a multicentre study, it was hospital based and therefore could be limited 
by tertiary referral bias, which might lead to an overestimation in severity. In line with this, we 
observed overall less severe disease with lower rates of cirrhosis and outcomes in the Dutch 
cohort, which comprised AIH patients managed predominantly at general, academic, and 
less frequently at transplant hospitals, whereas the UK cohort consisted of two transplant 
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centres. Nevertheless, as advanced health care is accessible through both the National 
Health Service in the UK and mandatory insurance policy in the Netherlands, this bias likely 
affects both groups. Hence it seems unlikely to account for the poorer outcome observed in 
black AIH patients, although the relatively small number of included black AIH patients in the 
Dutch cohort may explain the lack of association with outcome in the Dutch cohort due to 
lack of power. A recent study of the UK and USA national liver transplant registries reported 
that black patients were listed at younger age and had higher model for end-stage liver 
disease (MELD) scores than other races (Table 4.).25 Secondly, socioeconomic status, 
healthcare access and practice, and thus quality of care are factors that must be considered 
comparing disease characteristics and outcomes amongst different groups.26 For example, 
mortality differences between white and African descendent North Americans with cirrhosis 
disappear after adjustment for socio-economic status.27 The earlier age at diagnosis and 
similar cirrhosis rates argue against a systematic delay in the diagnosis of AIH in black 
patients, assuming that untreated disease progression rates are similar. The elevated 
hazard of liver transplantation or liver related death for black patients could be attributed to a 
more aggressive disease phenotype, which might progress despite similar rates of initial 
treatment response, which is supported by a recent population study in the USA (Table 4).13 
Unfortunately, Wen et al. did not report on the clinical characteristics, but relied on 
international classification of disease 9 codes. Conversely, the differences in liver-related 
mortality and liver transplantation could reflect variations in the quality and experience of 
care depending upon race. Lastly, it is possible that genetic variations may have been 
responsible for the worse outcome observed in black patients with AIH. There are well 
established differences between black and white patient groups regarding the incidence of 
SLE and other immunoinflammatory disorders such as sarcoidosis. Additionally, differences 
in other immune parameters such as ethnic neutropaenia28 and the distribution of the Duffy 
antigen receptor for chemokines polymorphisms29 suggest that genetic influences upon the 
immune system differ between populations. Previous studies have shown that genetic 
factors influence AIH occurrence, clinical expression and response to corticosteroid 
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therapy,6, 14, 30 but the genetic contributions to disease onset and phenotype of AIH have not 
been explored in patients of African or Caribbean descent. In white Northern European 
populations the HLA-DRB1*04:01 genotype was associated with a higher rate of remission 
and with a lower frequency of cirrhosis and need for liver transplantation.5 Interestingly, it 
has been shown that HLA-DR4 is under-represented in African Americans compared to 
Caucasian individuals.31 The current study provides no information about HLA class II 
genotypes, constituting one key limitation in interpreting the data. Additionally, common with 
other retrospective studies, our results may be influenced by referral bias, missing data, 
skewed outcome parameters and we cannot ascribe causality of poorer outcomes to race. 
As race was self-reported and categorised as black or white, we could not control for the 
likely genetic heterogeneity within these large groups. A further limitation is the lack of data 
on adherence to treatment within the studied groups. However, the strength of this study 
comprises the large catchment area in two different countries with accessible healthcare 
systems.  
Future, prospective studies are required to explore the mechanism, importance and 
generalizability of our findings. The impact of genetic variants amongst different racial 
groups in Europe, and globally, upon clinical outcomes would help inform our understanding 
of disease biology, aetiology and risk prediction. Qualitative and quantitative exploration of 
the experiences of patients and access to healthcare, capturing data on, amongst others, 
socio-economic status, race, gender and treatment centre should be performed. The 
proposed IAIHG retrospective and prospective registries offer a suitable starting point and 
further focused studies will be required.23, 24  
In summary, the results of this study show that the presentation and clinical course of AIH is 
different in black patients compared to a reference cohort of white AIH patients. Black AIH 
patients present at a younger age, with higher IgG levels and a higher prevalence of SLE 
than a white reference population. Black AIH patients appear to have a higher rate of 
transplantation and liver-related mortality, despite a similar disease stage at presentation. It 
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is likely that a combination of different factors may account for this observation, including 
time of diagnosis, treatment regimen, and genetic and environmental disparities between the 
different groups.  
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Legends 
Table 1. Baseline characteristics of black and white AIH patients 
Abbreviations: ALT, alanine-aminotransferase; ALP, alkaline phosphatase; AMA, anti-
mitochondrial antibodies; ANA, anti-nuclear antibodies; AST, aspartate-aminotransferase; 
IQR, interquartile range; IU/L, international units / liter; LKM-1, liver kidney microsome-1 
antibodies; SLE, systemic lupus erythematosus; SMA, anti-smooth muscle antibodies. 
Table 2. Therapy and outcome in black and white AIH patients  
Abbreviations: HCC, hepatocellular carcinoma; IQR, interquartile range. 
Table 3. Liver transplant and/or liver related death  
Cox regression analysis of combined liver transplant and/or liver related death  
Patients without biopsy at diagnosis were included in this analysis as not having cirrhosis. 
The multivariate analysis was conducted in 969 of 985 patients (98%) with available data for 
included variables. Abbreviations: HR, hazard ratio; SLE, systemic lupus erythematosus. 
Table 4. Summary of presentation, response and outcome the literature on black race 
and autoimmune hepatitis 
Figure 1. Flowchart of selection of AIH patients in the United Kingdom and the Dutch cohort. 
Abbreviations: AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary 
sclerosing cholangitis.  
Figure 2. Transplant free and liver related death survival analysis in the combined (A), Kings 
College Hospital, United Kingdom (B), Royal Free Hospital, United Kingdom (C), and Dutch 
cohort (D). 
 
Supplementary table 1. Baseline characteristics, therapy and outcome in black and 
white AIH patients in the UK cohort 
Abbreviations: ALT, alanine-aminotransferase; ALP, alkaline phosphatase; AMA, anti-
mitochondrial antibodies; ANA, anti-nuclear antibodies;  AST, aspartate-aminotransferase; 
HCC, hepatocellular carcinoma; IQR, interquartile range; IU/L, international units / liter; LKM-
1, liver kidney microsome-1 antibodies; SLE, systemic lupus erythematosus; SMA, anti-
smooth muscle antibodies. 
Supplementary table 2. Baseline characteristics, therapy and outcome in black and 
white AIH patients in the Dutch cohort 
Abbreviations: ALT, alanine-aminotransferase; ALP, alkaline phosphatase; AMA, anti-
mitochondrial antibodies; ANA, anti-nuclear antibodies;  AST, aspartate-aminotransferase; 
HCC, hepatocellular carcinoma; IQR, interquartile range; IU/L, international units / liter; LKM-
1, liver kidney microsome-1 antibodies; SLE, systemic lupus erythematosus; SMA, anti-
smooth muscle antibodies. 
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Table 1 Baseline characteristics 
 Black (n=88)  White (n=897)  p n 
Age at diagnosis (years), median 
(IQR) 
38 23-49 45 24-58 0.007 981 
Female, n (%) 67 76 700 78 0.7 985 
       
Post-treatment IAIHG score, 
median (IQR) 
20 17-22 19 17-22 0.9 941 
Definite post-treatment IAIHG 
score, n (%) 
61 69 665 74 0.3 985 
       
ALT or AST, (IU/L), median (IQR) 483 192-932 539 197-1080 0.8 850 
ALP (IU/L), median (IQR) 191 145-269 174 129-252 0.1 823 
Bilirubin (mmol/L), median (IQR) 57 30-165 55 19-180 0.7 810 
Creatinin (umol/L), median (IQR) 72 62-89 73 63-85 0.9 597 
INR, median (IQR) 1.2 1.1-1.6 1.2 1.0-1.4 0.082 634 
Albumin (g/L), mean (range) 32.8 16-46 35.1 15-55 0.005 762 
Peak IgG (g/L), mean (range) 31.0 4.6-91.1 27.5 4.8-89.5 0.043 748 
 
      
ANA positivity =>1:40, n (%) 58 68 572 69 0.8 909 
SMA positivity =>1:40, n (%) 47 55 478 60 0.4 890 
LKM-1 positivity =>1:40, n (%) 4 5 44 6 0.8 807 
AMA positivity =>1:80, n (%) 2 2 30 4 0.8 924 
 
      
SLE, n (%) 9 10 19 2 <0.001 985 
Thyroid disease, n (%) 8 9 127 14 0.2 983 
Hypothyroidism, n (%) 7 10 93 11  
 
Hyperthyroidism, n (%) 1 2 28 3  
 
Coeliac disease, n (%) 0 0 8 1 1.0 983 
 
      
Acute presentation (< 6 months), n 
(%) 
54 68 375 61 0.3 693 
Cirrhosis at diagnosis, n (%) 22 29 200 27 0.6 822 
 
      
Managed at transplant centre 71 81 651 73 0.1 985 
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Table 2 Therapy and outcome 
 Black (n=88)  White (n=897)  p n 
Therapy  
     
Steroids for induction, n (%) 84 99 841 95 0.2 971 
Azathioprine for maintenance, n (%) 59 75 703 81 0.2 949 
Ever on second-line therapy, n (%) 13 17 96 11 0.1 953 
 
      
Response to standard therapy, n (%) 67 86 773 91 0.1 928 
Relapse, n (%) 39 57 405 50 0.3 875 
Number of relapses, median (IQR) 1 0-3 1 0-2 0.018 815 
 
      
Outcome  
     
HCC, n (%) 2 2 23 3 1.0 973 
Liver transplantation, n (%) 12 14 49 6 0.002 984 
Livertransplantation + Liver related death, n (%) 19 22 100 11 0.004 985 
Overall death, n (%) 10 11 138 15 0.3 985 
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Table 3 Survival: Transplant and liver-related death 
 UK cohort  Dutch cohort  Overall  
  
 
Univariate  Univariate  Univariate  Mutivariate  
 
HR (95-CI) p HR (95-CI) p HR (95-CI) p HR (95-CI) p 
Black 2.5 (1.5-4.4) 0.001 1.6 (0.5-5.4) 0.4 2.5 (1.6-4.2) <0.001 2.4 (1.4-4.0) 0.001 
Age 1.0 (1.0-1.0) 0.6 1.0 (1.0-1.0) 0.012 1.0 (1.0-1.0) 0.14 1.0 (1.0-1.0) 0.049 
Gender 0.9 (0.5-1.5) 0.7 1.2 (0.5-2.7) 0.7 0.9 (0.6-1.5) 0.9  
 
Cirrhosis at 
diagnosis 
3.3 (2.1-5.1) <0.001 1.8 (0.9-3.9) 0.12 3.2 (2.2-4.5) <0.001 3.1 (2.1-4.4) <0.001 
SLE 2.7 (1.2-6.2) 0.02 1.0 (0.1-7.8) 0.9 2.3 (1.1-4.9) 0.035 1.9 (0.9-4.3) 0.12 
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Authors (y) Population n Presentation Response Outcome Study setting 
Lim et al. 
(2001) 8 
27 African Americans and 
24 white AIH patients 
Cirrhosis in 85% of African 
Americans and 38% of 
white patients 
Both groups responded 
well to therapy 
African Americans required 
higher prednisone doses than 
whites 
One tertiary 
referral center 
Zolfino et al. 
(2002) 9 
6 African and 5 Asian and 
1 Arabic AIH patients 
Cirrhosis in 1 of the African 
and 4 Asian patients 
Complete response in 2 
African, 2 Asian and 1 
Arabic patient. Partial or 
no response in 7 patients 
Death or transplantation in 2 
African (33%), 4 Asian (80%) 
and 1 (100%) Arabic patient 
One tertiary 
referral center 
Verma et al. 
(2007) 10 
37 Black and 64 non-black 
AIH patients  
Cirrhosis and acute 
presentation were more 
common in black than 
nonblack patients (57% vs 
38% and 76% vs 50%, 
respectively) 
Black patients were less 
likely to achieve 
remission (76%) than 
nonblack patients (90%) 
Black patients had a 4-fold 
higher mortality rate and were 
referred two times more often 
for transplantation than 
nonblack patients 
One tertiary 
referral center 
Wen et al. 
(2018) 13 
Hospitalizations for AIH in 
1.463 black and 4.666 
white AIH patients 
Cirrhosis in 12.5% of black 
and 15.1% of white 
patients 
Black patients were 
hospitalized for AIH at a 
rate 69% higher than 
whites 
Black patients had higher odds 
of death during hospitalization 
for AIH than white patients 
US Nationwide 
Inpatient Sample 
database (2008-
2012) 
Webb et al. 
(2018) 16 
Transplantation list: 796 
black and 3665 white AIH 
patients 
- - Black patients with AIH were 
listed for transplantation more 
than 10 years younger than 
white patients 
US and UK 
transplantation 
centers (1995-
2014) 
Lee et al. 
(2018) 12 
10 Black, 29 Latino and 19 
Asian Pacific Islander AIH 
and 2049 control patients 
Biochemistry and rates of 
cirrhosis were similar 
between the groups 
No difference in time to 
steroid discontinuation or 
clinical course between 
the groups 
Black, Latino and Asian Pacific 
Islander patients had almost ten 
times higher odds of AIH than 
whites  
One tertiary 
referral center 
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United Kingdom
N = 632 AIH patients
n = 72 black 
n = 560 white
Netherlands
N = 492 AIH patients
n = 20 black
n = 472 white
Combined
N = 985 AIH patients
n = 88 black
n = 897 white
n = 34 AIH-PBC
n = 0 black
n = 34 white
n = 34 AIH-PSC
n = 4 black
n = 30 white 
n = 31 AIH-PBC
n = 0 black
n = 31 white
n = 40 AIH-PSC
n = 0 black
n = 40 white
United Kingdom
N = 564 AIH patients
n = 68 black 
n = 496 white
Netherlands
N = 421 AIH patients
n = 20 black
n = 472 white
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What You Need to Know 
Background 
- Autoimmune hepatitis is a chronic inflammatory condition of the liver, that can 
manifest in all ethnic and racial groups 
- Genetics, ethnicity and race have an impact on the development of immune mediated 
conditions 
- Socioeconomic status may affect healthcare outcomes 
Findings 
- Autoimmune hepatitis patients of black background present at an earlier age than 
white patients 
- Black autoimmune hepatitis patients have a more severe disease course, with a 
higher chance of liver transplantation or death due to liver failure 
Implications for patient care 
- Black autoimmune hepatitis patients may need a more stringent therapeutic approach 
in order to prevent worse liver-related outcomes. 
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Table 1. Baseline characteristics, therapy and outcome of UK AIH patients 
 Black (n=68)  White (n=496)  p n 
Age at diagnosis (years), median 
(IQR) 
38 22-48 44 22-58 0.05 560 
Female, n (%) 52 77 391 79 0.7 564 
 
      
Post-treatment IAIHG score, 
median (IQR) 
20 17-22 20 18-23 0.15 520 
 
      
ALT or AST, (IU/L), median (IQR) 551 209-1044 586 199-1125 0.9 517 
ALP (IU/L), median (IQR) 194 146-291 183 136-273 0.3 501 
Bilirubin (mmol/L), median (IQR) 75 31-184 69 21-225 0.9 506 
Creatinin (umol/L), median (IQR) 75 65-89 73 63-88 0.5 313 
INR, median (IQR) 1.3 1.1-1.6 1.2 1.0-1.5 0.051 428 
Albumin (g/L), mean (range) 32.1 16-45 34.4 20-55 0.017 480 
Peak IgG (g/L), mean (range) 29.3 4.6-71.7 27.4 4.8-89.7 0.3 525 
 
      
ANA positivity =>1:40, n (%) 42 65 312 65 0.9 542 
SMA positivity =>1:40, n (%) 40 61 299 63 0.7 538 
LKM-1 positivity =>1:40, n (%) 3 5 29 6 0.8 545 
AMA positivity =>1:80, n (%) 2 3 19 4 1.0 545 
 
      
SLE, n (%) 7 10 11 2 0.003 564 
Thyroid disease, n (%) 7 10 93 19 0.092 562 
Hypothyroidism, n (%) 7 10 69 17  562 
Hyperthyroidism, n (%) 0 0 19 5  562 
Coeliacs disease, n (%) 0 0 6 1 1.0 562 
 
      
Acute presentation (< 6 months), n 
(%) 
43 67 267 58 0.2 521 
Cirrhosis at diagnosis, n (%) 20 34 144 32 0.8 509 
 
      
Managed at transplant centre 68 100 496 100 NA 564 
 
      
Therapy  
     
Steroids for induction, n (%) 65 100 480 99 1.0 551 
Azathioprine for maintenance, n (%) 41 70 375 80 0.064 528 
Ever on second-line therapy, n (%) 12 21 63 13 0.13 532 
Response to standard therapy, n 
(%) 
47 81 424 93 0.005 514 
Relapse, n (%) 25 52 191 46 0.4 462 
Number of relapses, median (IQR) 1 0-3 0 0-1 0.09 403 
 
      
Outcome  
     
HCC, n (%) 2 3 21 4 1.0 552 
Liver transplantation, n (%) 12 18 38 8 0.007 563 
Liver transplantation + Liver related 
death, n (%) 
16 24 67 14 0.029 564 
Overall death, n (%) 5 7 75 15 0.09 564 
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Table 2. Baseline characteristics, therapy and outcome in the Dutch cohort 
 
 Black (n=20)  White (n=401)  p n 
Age at diagnosis (years), median 
(IQR) 
38 27-50 46 28-59 0.2 421 
Female, n (%) 15 75 309 77 0.8 421 
    
   
Post-treatment IAIHG score, 
median (IQR) 
20 16-22 18 16-21 0.3 421 
 
   
   
ALT or AST, (IU/L), median (IQR) 378 166-526 492 185-1604 0.2 333 
ALP (IU/L), median (IQR) 170 87-212 158 117-236 0.8 322 
Bilirubin (mmol/L), median (IQR) 39 17-131 40 14-128 0.9 304 
Creatinin (umol/L), median (IQR) 62 55-78 73 63-83 0.2 292 
INR, median (IQR) 1.1 1.1-1.2 1.1 1.0-1.3 0.7 206 
Albumin (g/L), mean (range) 35.8 26-46 36.2 15-54 0.8 282 
Peak IgG (g/L), mean (range) 40.4 19.6-91.1 27.6 7.4-75.3 0.001 223 
 
      
ANA positivity =>1:40, n (%) 16 80 260 75 0.8 367 
SMA positivity =>1:40, n (%) 7 35 179 54 0.1 352 
LKM-1 positivity =>1:40, n (%) 1 6 15 6 1.0 262 
AMA positivity =>1:80, n (%) 0 0 11 3 1.0 379 
 
      
SLE, n (%) 2 10 8 2 0.08 421 
Thyroid disease, n (%) 1 5 34 9 1.0 421 
Hypothyroidism, n (%) 0 0 24 6  421 
Hyperthyroidism, n (%) 1 5 10 3  421 
Coeliacs disease, n (%) 0 0 2 1 1.0 412 
 
      
Acute presentation (< 6 months), 
n (%) 
11 69 108 69 1.0 172 
Cirrhosis at diagnosis, n (%) 2 13 56 19 0.7 313 
 
      
Managed at transplant centre, n 
(%) 
3 15 155 39 0.03 421 
 
      
Therapy  
     
Steroids for induction, n (%) 19 95 361 90 0.7 420 
Azathioprine for maintenance, n 
(%) 
18 90 328 82 0.5 421 
Ever on second-line therapy, n 
(%) 
1 5 33 8 1.0 421 
Response to standard therapy, n 
(%) 
20 100 349 89 0.1 414 
Relapse, n (%) 14 70 214 55 0.2 413 
Number of relapses, median (IQR) 2 0-4 1 0-2 0.038 412 
 
      
Outcome  
     
HCC, n (%) 0 0 2 1 1.0 421 
Liver transplantation, n (%) 0 0 11 3 1.0 421 
Livertransplantation + Liver 
related death, n (%) 
3 15 33 8 0.2 421 
Overall death, n (%) 5 25 63 16 0.3 421 
 
 
